BR112019000941A2 - derivados de aminopiridina e seu uso como inibidores seletivos de alk-2 - Google Patents

derivados de aminopiridina e seu uso como inibidores seletivos de alk-2

Info

Publication number
BR112019000941A2
BR112019000941A2 BR112019000941-8A BR112019000941A BR112019000941A2 BR 112019000941 A2 BR112019000941 A2 BR 112019000941A2 BR 112019000941 A BR112019000941 A BR 112019000941A BR 112019000941 A2 BR112019000941 A2 BR 112019000941A2
Authority
BR
Brazil
Prior art keywords
inhibitors
aminopyridine derivatives
compound
selective alk
alk
Prior art date
Application number
BR112019000941-8A
Other languages
English (en)
Inventor
Li Jialiang
Arista Luca
Babu Sreehari
Bian Jianwei
Cui Kai
Patrick Dillon Michael
Lattmann René
Liao Lv
Lizos Dimitrios
Ramos Rita
Johannes Stiefl Nikolaus
Ullrich Thomas
Usselmann Peggy
Wang Xiaoyang
Murlidhar Waykole Liladhar
Zhang Yubo
Weiler Sven
Zhu Tingying
Zhou Yizong
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112019000941A2 publication Critical patent/BR112019000941A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

patente de invenção: "derivados de aminopiridina e seu uso como inibidores seletivos de alk-2". a invenção refere-se a um composto de fórmula (i) em forma livre ou em forma de sal farmaceuticamente aceitável (i) para as composições farmacêuticas contendo o referido composto e ao uso do referido composto no tratamento da ossificação heterotópica e fibrodisplasia ossificante progressiva.
BR112019000941-8A 2016-07-20 2017-07-18 derivados de aminopiridina e seu uso como inibidores seletivos de alk-2 BR112019000941A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662364620P 2016-07-20 2016-07-20
US62/364,620 2016-07-20
PCT/CN2017/093385 WO2018014829A1 (en) 2016-07-20 2017-07-18 Aminopyridine derivatives and their use as selective alk-2 inhibitors

Publications (1)

Publication Number Publication Date
BR112019000941A2 true BR112019000941A2 (pt) 2019-04-30

Family

ID=60991950

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019000941-8A BR112019000941A2 (pt) 2016-07-20 2017-07-18 derivados de aminopiridina e seu uso como inibidores seletivos de alk-2

Country Status (25)

Country Link
US (3) US10710980B2 (pt)
EP (2) EP3971177A1 (pt)
JP (3) JP7030776B2 (pt)
KR (5) KR102454129B1 (pt)
CN (2) CN114014844A (pt)
AR (1) AR109108A1 (pt)
AU (4) AU2017298187B2 (pt)
BR (1) BR112019000941A2 (pt)
CA (1) CA3030332A1 (pt)
CY (1) CY1124967T1 (pt)
DK (1) DK3487851T3 (pt)
EA (2) EA037520B1 (pt)
ES (1) ES2902521T3 (pt)
HR (1) HRP20211868T1 (pt)
HU (1) HUE057328T2 (pt)
LT (1) LT3487851T (pt)
MX (2) MX2019000837A (pt)
PL (1) PL3487851T3 (pt)
PT (1) PT3487851T (pt)
RS (1) RS62819B1 (pt)
RU (1) RU2747318C2 (pt)
SI (1) SI3487851T1 (pt)
TW (4) TWI755255B (pt)
UY (1) UY37331A (pt)
WO (1) WO2018014829A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037520B1 (ru) * 2016-07-20 2021-04-07 Новартис Аг Производные аминопиридина и их применение в качестве селективных ингибиторов alk–2
EP4061367A1 (en) * 2019-11-22 2022-09-28 Incyte Corporation Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
CN111170893B (zh) * 2020-01-19 2022-04-26 郑州依米花手性药物研究有限公司 Lefamulin的中间体化合物及其在Lefamulin制备中的应用
WO2021257532A1 (en) 2020-06-16 2021-12-23 Incyte Corporation Alk2 inhibitors for the treatment of anemia
WO2023198114A1 (zh) * 2022-04-13 2023-10-19 杭州邦顺制药有限公司 Alk2激酶抑制剂

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077290A (en) 1990-10-11 1991-12-31 Merck & Co., Inc. Morpholine derivatives compositions and use
JP3362151B2 (ja) 1992-11-17 2003-01-07 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ アクチビンレセプター状キナーゼ活性を有するタンパク質をコードする単離核酸分子、及び、これを用いた発現ベクタ、組み換え細胞、単離タンパク質、単離抗体
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
US6914058B2 (en) * 2002-01-18 2005-07-05 Dr. Reddy's Laboratories, Limited Antibacterial compounds: process for their preparation and pharmaceutical compositions containing them
EP1501514B1 (en) 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
US7015227B2 (en) 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
US20040067985A1 (en) 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
SE0203753D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JP2007521252A (ja) 2003-04-11 2007-08-02 エスジーエックス ファーマシューティカルズ，インコーポレイティド 化合物ライブラリーおよび薬剤発見方法
WO2005115985A1 (en) 2004-05-27 2005-12-08 Pfizer Limited Aminopyridine derivatives as selective dopamine d3 agonists
SA05260265A (ar) 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
CA2603959A1 (en) 2005-04-08 2006-10-19 Eisai R & D Management Co., Ltd. Therapeutic agent for dyskinesia
WO2007011760A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
GB0517175D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
PE20071241A1 (es) 2006-01-17 2008-01-14 Schering Corp Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios
US8895711B2 (en) 2006-04-18 2014-11-25 The Trustees Of The University Of Pennsylvania Mutated ACVR1 for diagnosis and treatment of Fibrodyplasia Ossificans Progressiva (FOP)
WO2008002671A2 (en) 2006-06-29 2008-01-03 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors
KR20090088852A (ko) 2006-09-05 2009-08-20 메다렉스, 인코포레이티드 골형성 단백질의 항체와 이의 수용체 및 이의 사용방법
US20100093760A1 (en) 2006-09-12 2010-04-15 The General Hospital Corporation Methods for identifying compounds that modulate cell signaling and methods employing such compounds
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
WO2010008739A2 (en) 2008-06-20 2010-01-21 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
CN103079585B (zh) 2010-08-20 2015-09-30 惠氏有限责任公司 经设计的成骨蛋白
AU2011340167A1 (en) 2010-12-06 2013-07-18 Piramal Enterprises Limited Substituted imidazoquinoline derivatives
WO2012087938A1 (en) 2010-12-20 2012-06-28 Glaxosmithkline Llc Quinazolinone derivatives as antiviral agents
US8987271B2 (en) 2010-12-22 2015-03-24 Eutropics Pharmaceuticals, Inc. 2,2′-biphenazine compounds and methods useful for treating disease
BR112013029640A2 (pt) 2011-05-23 2017-06-13 Merck Patent Gmbh derivados de piridina e pirazina
TWI568714B (zh) 2011-09-09 2017-02-01 藍瑟斯醫學影像公司 用於合成及使用造影劑之組合物、方法及系統
JP6430383B2 (ja) * 2012-09-28 2018-11-28 ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ 選択的ｂｍｐ阻害剤としての縮合複素環化合物
US20160115167A1 (en) * 2013-03-04 2016-04-28 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
EP2970311A4 (en) 2013-03-14 2016-11-23 Brigham & Womens Hospital BMP INHIBITORS AND METHODS OF USE
ES2738493T3 (es) * 2013-03-14 2020-01-23 Tolero Pharmaceuticals Inc Inhibidores de JAK2 y ALK2 y métodos para su uso
PT3060550T (pt) 2013-10-21 2019-08-27 Merck Patent Gmbh Compostos de heteroarilo como inibidores de btk e utilizações dos mesmos
WO2015152183A1 (ja) 2014-03-31 2015-10-08 大日本住友製薬株式会社 進行性骨化性線維異形成症の予防剤及び治療剤
CN107257793A (zh) 2015-01-20 2017-10-17 梅里亚股份有限公司 抗蠕虫化合物、组合物及其使用方法
EA037520B1 (ru) 2016-07-20 2021-04-07 Новартис Аг Производные аминопиридина и их применение в качестве селективных ингибиторов alk–2
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation

Also Published As

Publication number Publication date
EP3487851A1 (en) 2019-05-29
US20210155606A1 (en) 2021-05-27
AU2023200265A1 (en) 2023-02-16
TW202336011A (zh) 2023-09-16
PT3487851T (pt) 2022-01-07
EP3487851B1 (en) 2021-10-20
TW201805277A (zh) 2018-02-16
MX2021014852A (es) 2022-01-18
EP3487851A4 (en) 2019-12-25
EA201990343A1 (ru) 2019-06-28
KR102559539B1 (ko) 2023-07-26
RU2019104609A3 (pt) 2020-09-30
TWI712598B (zh) 2020-12-11
WO2018014829A1 (en) 2018-01-25
TW202220969A (zh) 2022-06-01
US20200299265A1 (en) 2020-09-24
RU2019104609A (ru) 2020-08-20
EA037520B1 (ru) 2021-04-07
KR102359707B1 (ko) 2022-02-09
KR20190026917A (ko) 2019-03-13
HUE057328T2 (hu) 2022-05-28
RS62819B1 (sr) 2022-02-28
PL3487851T3 (pl) 2022-04-11
ES2902521T3 (es) 2022-03-28
JP7030776B2 (ja) 2022-03-07
AU2017298187B2 (en) 2019-11-14
AU2021201424C1 (en) 2023-02-02
HRP20211868T1 (hr) 2022-03-04
RU2021111037A (ru) 2021-05-13
AU2021201424B2 (en) 2022-10-20
RU2747318C2 (ru) 2021-05-04
US10947218B2 (en) 2021-03-16
SI3487851T1 (sl) 2022-03-31
MX2019000837A (es) 2019-07-04
TWI755255B (zh) 2022-02-11
TW202134228A (zh) 2021-09-16
KR102454129B1 (ko) 2022-10-14
KR20210094138A (ko) 2021-07-28
AR109108A1 (es) 2018-10-31
KR20220021023A (ko) 2022-02-21
AU2019246857A1 (en) 2019-10-31
KR102281550B1 (ko) 2021-07-27
CY1124967T1 (el) 2023-01-05
CN109641871B (zh) 2021-10-22
JP2022078137A (ja) 2022-05-24
CN109641871A (zh) 2019-04-16
JP7253086B2 (ja) 2023-04-05
CA3030332A1 (en) 2018-01-25
TWI806385B (zh) 2023-06-21
KR20220143770A (ko) 2022-10-25
JP2019521167A (ja) 2019-07-25
UY37331A (es) 2018-02-28
AU2021201424A1 (en) 2021-03-25
CN114014844A (zh) 2022-02-08
EA202190285A1 (ru) 2021-08-31
US20190161474A1 (en) 2019-05-30
US10710980B2 (en) 2020-07-14
RU2021111037A3 (pt) 2022-02-10
KR20230117248A (ko) 2023-08-07
DK3487851T3 (da) 2021-12-20
AU2017298187A1 (en) 2018-12-20
EP3971177A1 (en) 2022-03-23
LT3487851T (lt) 2021-12-27
AU2019246857B2 (en) 2020-12-24
JP2023089012A (ja) 2023-06-27

Similar Documents

Publication Publication Date Title
BR112019000941A2 (pt) derivados de aminopiridina e seu uso como inibidores seletivos de alk-2
CY1123595T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5
CY1122566T1 (el) Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου
BR112016029853A2 (pt) compostos de indazol substituído como inibidores de irak4
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112015018738A8 (pt) compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
BR112015029455A8 (pt) compostos químicos, uso, métodos e composições para prevenção ou tratamento de câncer
EA201690752A1 (ru) Ингибиторы g12c kras
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
BR112015016911A2 (pt) tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn
AR090292A1 (es) Compuestos basados en pirazolo[1,5-a]pirimidina, composiciones que los comprenden y metodos que los utilizan
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
EA201591301A1 (ru) Новые пиримидиновые и пиридиновые соединения и их применение
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
EA201790337A1 (ru) Кристаллические формы ингибиторов глутаминазы
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
BR112015029353A2 (pt) derivados de pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças
DOP2014000059A (es) Derivados de estra–1,3,5(10),16–tetraen–3–carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
ECSP15000868A (es) Derivados de estra–1,3,5(10),16–tetraeno 3–sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
AU2017269673A1 (en) Pyridine dicarboxamide derivatives as bromodomain inhibitors
BR112019007763A2 (pt) composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]